Amyloid-β Clearance Mechanisms in Alzheimer's Disease
About this study
The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. In order to achieve this aim the investigators intend to study participants with a Subjective Cognitive Decline, Mild Cognitive Impairment and a mild Alzheimer's disease.
- Condition
- Alzheimer's Disease (AD)
- Tested
- positron emission tomography (PET)
- Sponsor
- Ludwig-Maximilians - University of Munich
Who can join
- Age
- 50 to 85 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 50 years
- Maximum age: 85 years
- Study condition: Alzheimer's Disease (AD)
- Diagnosis of amnestic MCI or AD dementia or clinical normal
- Able to provide written informed consent
- Unchanged pharmacotherapy within 4 days prior to the study specific assessments
- Fluent in German
Exclusion 15
- Unable to give informed consent or has a legal guardian
- Other severe mental disorder, e.g. schizophrenia or bipolar affective disorder
- Clinically relevant depression
- Acute suicidality
- Current alcohol, drug or medication abuse
- History of severe traumatic brain injury within 3 months prior to inclusion
- Structural lesions of the basal ganglia or brain stem
- Severe neurological disorder including (but not limited to) epilepsy, systemic disorders, stroke, repeated transient ischaemic attacks, increased brain intracranial pressure, normal pressure hydrocephalus
- Severe medical disorders including (but not limited to) heart failure, respiratory failure, uncontrolled severe arterial hypertension
- Electronic implants (e.g. cardiac pacemaker) or other MRI contraindication
- Renal failure \> stage 3 (GFR \< 30 mL/min)
- Pregnancy
- Unresolved malignancies within two years prior to inclusion
- Severe current infections or other chronic or systemic disorders
- Other circumstances which preclude participation based on the investigator's judgement
Where
1 site, 1 recruiting
Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums
München, Bavaria, Germany
Contact
-
Robert Perneczky, Prof.Dr.med.
+4989440055863 PSY.Alzheimerzentrum@med.uni-muenchen.de
-
Lena Burow, M.Sc.
+4989440055898 lena.burow@med.uni-muenchen.de
Potential match only. Final eligibility is determined by the study team.